Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signal regulatory protein gamma (SIRPγ) is a member of the SIRP family of receptor-type transmembrane glycoproteins. SIRPγ is uniquely expressed on human T-cells and binds to CD47 on antigen-presenting cells, mediating cell-cell adhesion. It functions as a checkpoint regulator for human effector T-cells; reduced expression can potentiate effector responses. Genetic variants and altered expression have been associated with autoimmune diseases like type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus. While structurally similar to other SIRP family members, its short cytoplasmic tail means it does not directly transmit intracellular signals.
Modulates intercellular interactions; considered "nonsignaling" due to the lack of classical signaling motifs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Signal Regulatory Protein Gamma (SIRPγ).